Centessa Looks To Transform Drug Development With ‘Asset Centric’ Model
Company Bags $250m In Series A
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.